The Frequency of SARS-CoV-2 Anti-spike RBD IgG Antibodies in the Fully Vaccinated and Recovered COVID-19 Infected Individuals. | ||
| Advances in Environmental and Life Sciences | ||
| Volume 3, Issue 1, January 2023, Pages 31-40 PDF (942.73 K) | ||
| Document Type: Original research articles | ||
| DOI: 10.21608/aels.2022.176421.1023 | ||
| Authors | ||
| Amany Mohamed Elshamy1; Reda Salem2; Noha Kamel* 3; Mai Hussein2; Soha Younes3; Ohoud Mohamed Marie4 | ||
| 1Medical Laboratory Science Department, High Technology Institute of Applied Health Sciences, Badr Academy, Badr City, Cairo, Egypt. | ||
| 2Agricultural Genetic Engineering, Research Institute (AGERI), ARC, Giza 12619, Egypt | ||
| 3Clinical Pathology Department, Faculty of Medicine, Suez Canal University, 4.5 K, Ring Road, Ismailia 41511, Egypt | ||
| 4Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt | ||
| Abstract | ||
| Background: SARS-CoV-2 genome encodes different kinds of structural and nonstructural proteins. The spike structural protein is the prime target for vaccine manufacturing, drug development, and diagnostic assays. Methods: In this cross-sectional study, we assessed the developed Receptor Binding Domain (RBD) protein in 520 serum samples. The samples were stratified according to vaccine status into two groups: Group 1 consisted of 274 pre-vaccinated samples collected from April to December 2020 (109 were asymptomatic contacted with COVID-19-patients; 100 patients had positive RT-PCR test for SARS-CoV-2 infection, and 65 were convalescent-COVID-19 cases), and group 2 consisted of 246 post-vaccinated participants with or without past-infection recruited from students, coworkers, and staff members from November 2021 to March 2022. Indirect Enzyme-Linked Immunosorbent Assay (ELISA) was performed to evaluate the seroprevalence of the SARS-CoV-2 immunoglobulin G (IgG) across both groups. Results: The sensitivity and specificity of the RBD-developed protein were 88.4% (95% CI: 84% - 92%) and 100% (95% CI: 88%- 100%), respectively in the pre-vaccinated group. 213 out of 274 of the pre-vaccinated samples were positive. Meanwhile, the RBD-developed protein provided 100% RBD IgG seropositivity in the recovered COVID-19 cases. Moreover, the results were seropositive in all post-vaccinated candidates (n=246) and the results were reliable in 70 negative pre-pandemic sera specimens. Conclusion: The developed S-RBD protein has the potential to be a successful screening method in COVID-19-vaccinated or infected individuals. | ||
| Keywords | ||
| Keywords: Recombinant Spike RBD protein; SARS-CoV-2; ELISA; Vaccination | ||
|
Statistics Article View: 355 PDF Download: 232 |
||
